Makoto Hamasaki

Makoto Hamasaki

Auto-generated profile, based on publicly available information

Makoto Hamasaki

Department of Pathology Fukuoka University School of Medicine and Hospital Fukuoka Japan

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2019 in Histopathology
Verified
Journal Article
Closed access
PDF file
MHMakoto Hamasaki
Makoto Hamasaki
YKYoshiaki Kinoshita
Yoshiaki Kinoshita
MYMasayo Yoshimura
Masayo Yoshimura
SMShinji Matsumoto
Shinji Matsumoto
TKToshiaki Kamei
Toshiaki Kamei
KNKazuki Nabeshima
Kazuki Nabeshima

1 April 2009 in Cancer Science
Verified
Journal Article
Open access
PDF file
MNMotomichi Nakagawa
Motomichi Nakagawa
KNKazuki Nabeshima
Kazuki Nabeshima
SAShigeyuki Asano
Shigeyuki Asano
MHMakoto Hamasaki
Makoto Hamasaki
NUNoriko Uesugi
Noriko Uesugi
HIHiroshi Iwasaki
Hiroshi Iwasaki
Metalloproteinase activities of a disintegrin and metalloproteinases (ADAMs), matrix metalloproteinases (MMPs), and membrane type (MT-)MMPs are involved in many aspects of tumor biology. ADAMs are transmembrane proteins that cleave membrane-anchored proteins to release soluble factors, and thereby mediate important biological phenomena in tumors. The aim of this study was to analyze histopathology, expression and roles of metalloproteinases, especially ADAMs, in gastric gastrointestinal stromal tumor (GIST). Histopathology and immunohistochemical expression of ADAMs were examined in 89 gastric GISTs. In 11 GISTs, ADAM expression was examined at mRNA and protein levels by reverse transcription-polymerase chain reaction (RT-PCR) and immunoblotting, respectively. RT-PCR analysis showed frequent expression of ADAM9 (91%), ADAM10 (64%), ADAM17 (82%), MMP-2 (82%), and MT1-MMP (73%). However, ADAM17 and MMP-2 were the only metalloproteinases that were up-regulated in GISTs at the protein level compared with non-neoplastic gastric tissues. ADAM17 was immunohistochemically expressed in 93% of GIST versus 16% of normal gastric tissues. Furthermore, CD117-positive interstitial cells of Cajal in normal gastric tissues were all negative for ADAM17 with double immunostaining. Expressions of epidermal growth factor receptor (EGFR) and several EGFR ligands such as amphiregulin, heparin-binding epidermal growth factor (HB-EGF), betacellulin, and epiregulin were also demonstrated in GIST by RT-PCR. Protein expression of EGFR, phosphorylated EGFR, amphiregulin, and HB-EGF, both of which can be shed by ADAM17, was confirmed in tumors coexpressing ADAM17 by immunoblotting. Moreover, proteolytically cleaved soluble forms of amphiregulin were identified in tumor extracts. Considered together, the results suggest that ADAM17 may contribute to the progression and growth of GIST through shedding of EGFR ligands and consequent EGFR stimulation. ADAM17, as a major sheddase in GIST, could be potentially a suitable target in anticancer treatment of imatinib-resistant GISTs.

11 November 2008 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
TKTakehito Kawakami
Takehito Kawakami
KNKazuki Nabeshima
Kazuki Nabeshima
MHMakoto Hamasaki
Makoto Hamasaki
AIAkinori Iwasaki
Akinori Iwasaki
TSTakayuki Shirakusa
Takayuki Shirakusa
HIHiroshi Iwasaki
Hiroshi Iwasaki

12 September 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MAMikiko Aoki
Mikiko Aoki
KKK. Koga
K. Koga
MMM. Miyazaki
M. Miyazaki
MHM. Hamasaki
M. Hamasaki
NKNaohiko Koshikawa
Naohiko Koshikawa
KNK. Nabeshima
K. Nabeshima
Background: Interaction between cancer cells and fibroblasts mediated by extracellular matrix metalloproteinase inducer (emmprin, CD147) is important in the invasion and proliferation of cancer cells. However, the exact mechanism of emmprin mediated stimulation of matrix metalloprotease-2 (MMP-2) production from fibroblasts has not been elucidated. Our previous studies using an inhibitory peptide against emmprin suggested the presence of a molecule on the cell membrane which forms a complex with emmprin. Here we show that CD73 expressed on fibroblasts interacts with emmprin and is a required factor for MMP-2 production in co-cultures of sarcoma cells with fibroblasts.Methods: CD73 along with CD99 was identified by mass spectrometry analysis as an emmprin interacting molecule from a co-culture of cancer cells (epithelioid sarcoma cell line FU-EPS-1) and fibroblasts (immortalized fibroblasts cell line ST353i). MMP-2 production was measured by immunoblot and ELISA. The formation of complexes of CD73 with emmprin was confirmed by immunoprecipitation, and their co-localization in tumor cells and fibroblasts was shown by fluorescent immunostaining and proximity ligation assays.Results: Stimulated MMP-2 production in co-culture of cancer cells and fibroblasts was completely suppressed by siRNA knockdown of CD73, but not by CD99 knockdown. MMP-2 production was not suppressed by CD73-specific enzyme inhibitor (APCP). However, MMP-2 production was decreased by CD73 neutralizing antibodies, suggesting that CD73-mediated suppression of MMP-2 production is non-enzymatic. In human epithelioid sarcoma tissues, emmprin was immunohistochemically detected to be mainly expressed in tumor cells, and CD73 was expressed in fibroblasts and tumor cells: emmprin and CD73 were co-localized predominantly on tumor cells.Conclusion: This study provides a novel insight into the role of CD73 in emmprin-mediated regulation of MMP-2 production.

1 January 2015 in Lung Cancer
Verified
Journal Article
Closed access
SMSo Miyahara
So Miyahara
MHMakoto Hamasaki
Makoto Hamasaki
DHDaisuke Hamatake
Daisuke Hamatake
SYShin-Ichi Yamashita
Shin-Ichi Yamashita
TSTakeshi Shiraishi
Takeshi Shiraishi
KNKazuki Nabeshima
Kazuki Nabeshima

24 December 2015 in SpringerPlus
Verified
Journal Article
Open access
PDF file
YOYasuko Okado
Yasuko Okado
MAMikiko Aoki
Mikiko Aoki
MHMakoto Hamasaki
Makoto Hamasaki
KKKaori Koga
Kaori Koga
TSTakayuki Sueta
Takayuki Sueta
KNKazuki Nabeshima
Kazuki Nabeshima
Squamous cell carcinoma (SCC) of the external auditory canal (EAC) is rare, usually presents at an advanced stage, and is a more aggressive tumor with poor prognosis. The University of Pittsburgh TNM staging system commonly used in prognostication is not perfect, and more accurate biomarkers predicting prognosis are needed. Tumor budding is an established negative prognostic factor at the invasive front in colorectal cancer. Moreover, immunohistochemical studies showed that laminin 5-γ2 (Ln5-γ2) is expressed at the invasive front in tumor or tumor budding cells. We assessed the prognostic significance of tumor budding and Ln5-γ2 expression by performing Ln5-γ2 immunohistochemistry and evaluated the degree of tumor budding in pre-treatment biopsy specimens, and investigated their correlations to clinicopathological parameters in patients with SCC of the EAC. Patients whose tumors had high budding grade and Ln5-γ2 expression had significantly shorter survival times. Budding grade was significantly correlated with Ln5-γ2 expression. Multivariate analysis revealed that high budding grade predicted poorer prognosis regardless of disease stage. Our results suggested that budding grade and Ln5-γ2 expression can be used as indicators of poor prognosis in patients with SCC of the EAC.